Zelnorm returns
Executive Summary
Novartis drug will be available under a treatment investigational new drug protocol to treat irritable bowel syndrome with constipation and chronic idiopathic constipation in women under 55, FDA announces July 27. Marketing of tegaserod maleate was suspended in March after a pooled data analysis of 29 clinical trials revealed a higher chance of heart attack, stroke and worsening heart chest pain in patients treated with Zelnorm compared to those on placebo (1"The Pink Sheet" April 2, 2007, p. 3)...